PDE5A and melanoma: Any increase in malignant melanoma risk that is caused by PDE5 inhibitors would have serious public health implications (e.g., 5%–20% of men are affected by ED).[11,12] Moreover, the patent of sildenafil and other PDE5 inhibitors have expired or are soon going to expire in various countries, which lead to the availability of less costly generic versions and the potential for considerably inflated demand in the near future.